Galapagos NV : Galapagos discovers novel candidate drug to treat breast cancer
oGLPG1790 has high efficacy against triple-negative breast cancer
oInnovative, targeted approach
oGalapagos plans to initiate clinical trials within one year
Mechelen, Belgium; 22 April 2013 - Galapagos NV (Euronext: GLPG) announced
today that it developed GLPG1790, a novel candidate drug to treat breast
cancer. GLPG1790 has shown high activity against breast tumors that are
triple-negative, for which the absence of estrogen (ER), progesterone (PR) or
HER2 receptors affects the prognosis for recovery, and no targeted therapeutic
options are currently available.
Breast cancer is a disease in which tumor cells form in the breast tissue; it
is one of the most common types of cancer in women. There are many different
types of breast cancer, and as a result, there are many options for
treatment. Targeted drug treatments such as Herceptin^® and
Avastin^®^attack specific types of breast cancer cells. Decisions about
the best possible treatment with targeted drugs are based on tests for the
presence of ER, PR and HER2^. Triple-negative breast cancer (tumor cells
that have no ER, PR and HER2) accounts for one-fifth of breast cancers, and it
usually affects young women. There are no targeted drugs available for
patients with triple-negative breast cancer.
Candidate drug GLPG1790 is a selective and potent inhibitor of a novel breast
cancer target; the candidate drug has proven to be highly active against
triple-negative breast cancer in a mouse xenograft model where it completely
blocks tumor growth. GLPG1790 has good drug-like properties, and
safety/tolerability studies with the candidate drug look favorable. Galapagos
will initiate preclinical studies with GLPG1790, and expects to initiate the
first clinical trials in humans within one year. This novel program is fully
proprietary to Galapagos.
"GLPG1790 is the result of a multi-year research program on a novel mechanism
of action discovered with our target discovery platform," says Dr Piet
Wigerinck, Galapagos CSO. "We are pleased to have developed a targeted
approach towards triple-negative breast cancer. Targeted approaches in
oncology typically show good efficacy and less toxicity than chemotherapy."
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline of four clinical, seven pre-clinical,
and 30 discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778,
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
receptor antagonist currently in a Phase 1b patient study in metastasis.
GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program will start a Proof of Concept Phase 2 study
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
Dr Piet Wigerinck, Chief Scientific Officer
Tel. +32 477 627103
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
Herceptin^® and Avastin^® are registered trademarks of Roche for
trastuzumab and bevacizumab, respectively
Human epidermal growth factor type 2 receptor
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.